Biohaven Ltd. Investment Income, Investment Expense
Biohaven Ltd. (BHVN) reported Investment Income, Investment Expense of $24.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInvestmentExpense · last filed 2026-08-10
- Biohaven Ltd. investment income, investment expense for the quarter ending 2026-06-30 was $24.00K, a 46.67% decline year-over-year.
- Biohaven Ltd. investment income, investment expense for the quarter ending 2026-03-31 was $26.00K, a 21.21% decline year-over-year.
- Biohaven Ltd. investment income, investment expense for the quarter ending 2025-12-31 was $15.00K, a 75.81% decline year-over-year.
- Biohaven Ltd. investment income, investment expense for the quarter ending 2025-09-30 was $42.00K, a 6.67% decline year-over-year.
- Biohaven Ltd. investment income, investment expense for fiscal 2025 was $135.00K, a 23.73% decline from fiscal 2024.
- Biohaven Ltd. investment income, investment expense for fiscal 2024 was $177.00K, a 25.00% decline from fiscal 2023.
- Biohaven Ltd. investment income, investment expense for fiscal 2023 was $236.00K, a 774.07% increase from fiscal 2022.
- Biohaven Ltd. investment income, investment expense for fiscal 2022 was $27.00K.
| Period end | Investment Income, Investment Expense 3 month | Investment Income, Investment Expense 6 month | Investment Income, Investment Expense 9 month | Investment Income, Investment Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.00K 10-Q · filed 2026-08-10 | $50.00K 10-Q · filed 2026-08-10 | $65.00K derived: sum of 3 quarters · filed 2026-08-10 | $107.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-04 | $41.00K derived: sum of 2 quarters · filed 2026-05-04 | $83.00K derived: sum of 3 quarters · filed 2026-05-04 | $128.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $57.00K derived: sum of 2 quarters · filed 2026-03-02 | $102.00K derived: sum of 3 quarters · filed 2026-08-10 | $135.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $42.00K 10-Q · filed 2025-11-10 | $87.00K derived: sum of 2 quarters · filed 2026-08-10 | $120.00K 10-Q · filed 2025-11-10 | $182.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $45.00K 10-Q · filed 2026-08-10 | $78.00K 10-Q · filed 2026-08-10 | $140.00K derived: sum of 3 quarters · filed 2026-08-10 | $185.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $33.00K 10-Q · filed 2026-05-04 | $95.00K derived: sum of 2 quarters · filed 2026-05-04 | $140.00K derived: sum of 3 quarters · filed 2026-05-04 | $180.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $107.00K derived: sum of 2 quarters · filed 2026-03-02 | $147.00K derived: sum of 3 quarters · filed 2026-03-02 | $177.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $45.00K 10-Q · filed 2025-11-10 | $85.00K derived: sum of 2 quarters · filed 2025-11-10 | $115.00K 10-Q · filed 2025-11-10 | $148.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $40.00K 10-Q · filed 2025-08-11 | $70.00K 10-Q · filed 2025-08-11 | $103.00K derived: sum of 3 quarters · filed 2026-03-02 | $168.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $30.00K 10-Q · filed 2025-05-12 | $63.00K derived: sum of 2 quarters · filed 2026-03-02 | $128.00K derived: sum of 3 quarters · filed 2026-03-02 | $196.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $98.00K derived: sum of 2 quarters · filed 2026-03-02 | $166.00K derived: sum of 3 quarters · filed 2026-03-02 | $236.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $65.00K 10-Q · filed 2024-11-12 | $133.00K derived: sum of 2 quarters · filed 2024-11-12 | $203.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $68.00K 10-Q · filed 2024-08-09 | $138.00K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $70.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $27.00K 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |